Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Human melanocortin 4 receptor (hMC4R) mutations with in vitro functional effects are responsible for 0.5–2.5% of severe obesity. Designing ligands that are able to counteract this in vitro-associated molecular defect is crucial to develop specific anti-obesity drugs in these genetically associated cases. We analyzed the in vitro effect of two novel melanocortin agonists, IRC-022493 and IRC-022511, on typical hMC4R mutations chosen based on the nature of their functional alterations, i.e. intracytoplasmic retention and/or reduced basal activity and/or reduced α-MSH potency. We assessed the in vitro ability of IRC-022493 and IRC-022511 to bind and activate hMC4R mutants. These mutations were found earlier in 11 obese French patients (median age (range) was 17.6 years (5.7–48.0) and body mass index (BMI)-Z-score 4.2 s.d. (1.5–5.5). The MC4R agonists were responsible for a significant activation of mutated hMC4R depending on the functional characteristics of the mutations. Both agonists were able to activate mutated hMC4R with decreased α-MSH potency, associated with or without decreased basal activity, to the same extent than α-MSH in wild-type MC4R. This result suggests that those mutations would be the best targets for the MC4R agonists among MC4R mutation-bearing obese patients. No specific clinical phenotype was associated with the differential response to pharmacological agonists. We identified two novel melanocortin agonists that were able in vitro to efficiently activate mutated hMC4R with impaired endogenous agonist functional response. These results stimulate interest in the development of these drugs for hMC4R mutations-associated obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene
Farooqi, I. S., Keogh, J. M., Yeo, G. S. H., Lank, E. J., Cheetham, T., & O'Rahilly, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022050 · Cited by 1,778
Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity
Vaisse, C., Clement, K., Durand, E., Hercberg, S., Guy-Grand, B., & Froguel, P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9238 · Cited by 897 · cited 3×
“Taken together, these results being similar to previous ones (Vaisse et al .”
ResultInfluentialModulation of Blood Pressure by Central Melanocortinergic Pathways
Greenfield, J. R., Miller, J. W., Keogh, J. M., Henning, E., Satterwhite, J. H., Cameron, G. S., Astruc, B., Mayer, J. P., Brage, S., See, T. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0803085 · Cited by 477 · cited 1×
“However, a very recent clinical study showed the influence of a pharmacological agonist on blood pressure and underlined the interest of MC4R agonist administration to MC4R mutation carriers since they had lower blood pressure than MC4R wild-type carriers (Greenfield et al .”
BackgroundThe central melanocortin system directly controls peripheral lipid metabolism
Nogueiras, R., Wiedmer, P., Perez-Tilve, D., Veyrat-Durebex, C., Keogh, J. M., Sutton, G. M., Pfluger, P. T., Castaneda, T. R., Neschen, S., Hofmann, S. M., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31743 · Cited by 396
Unraveling the Genetics of Human Obesity
Mutch, D. M., & Clément, K. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020188 · Cited by 169
Self-citation
Cited by
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
Collet, T.-H., Dubern, B., Mokrosinski, J., Connors, H., Keogh, J. M., Mendes de Oliveira, E., Henning, E., Poitou-Bernert, C., Oppert, J.-M., Tounian, P., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.015 · Cited by 302
Self-citationFani, L., Bak, S., Delhanty, P., van Rossum, E. F. C., & van den Akker, E. L. T. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.80 · Cited by 121
The Neuroendocrine Circuitry Controlled by POMC, MSH, and AGRP
Biebermann, H., Kühnen, P., Kleinau, G., & Krude, H. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-24716-3_3 · Cited by 70
“are able to efficiently activate loss-of-function MC4Rmutations (Roubert et al. 2010).”
Background
Metadata
- Authors
- Roubert, P., Dubern, B., Plas, P., Lubrano-Berthelier, C., Alihi, R., Auger, F., Deoliveira, D. B., Dong, J. Z., Basdevant, A., Thurieau, C., & Clément, K.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2010-08-09
- Volume
- 207
- Issue
- 2
- Pages
- 177-183
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2143613118
- Cited by
- 40
- References
- 5
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response. https://app.cochat.ai/papers/10.1677/joe-09-0336
- The paper
- Roubert, P., Dubern, B., Plas, P., Lubrano-Berthelier, C., Alihi, R., Auger, F., Deoliveira, D. B., Dong, J. Z., Basdevant, A., Thurieau, C., & Clément, K. (2010). Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response. Journal of Endocrinology. https://doi.org/10.1677/joe-09-0336
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.